Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands

Oncology
2
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

MeiraGTx
MeiraGTxNEW YORK, NY
2 programs
2
AAV2-hAQP1Phase 21 trial
AAV2-hAQP1 Concentration 1Phase 21 trial
Active Trials
NCT06544798Enrolling By InvitationEst. Feb 2032
NCT05926765RecruitingEst. Dec 2026

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
2029
2030
2031
MeiraGTxAAV2-hAQP1
MeiraGTxAAV2-hAQP1 Concentration 1

Clinical Trials (2)

Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia

Start: Aug 2024Est. completion: Feb 2032
Phase 2Enrolling By Invitation
NCT05926765MeiraGTxAAV2-hAQP1 Concentration 1

A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia

Start: Jun 2023Est. completion: Dec 2026
Phase 2Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials
1 companies competing in this space